Can a Precision-Engineered transplant rebuild immunity in babies born without it?

NCT ID NCT03597594

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Infants with severe combined immunodeficiency (SCID) lack working immune cells and face life-threatening infections. A matched sibling donor transplant is the standard cure, but most babies do not have one. This trial tests a refined transplant using a parent or other partially matched donor, with specific immune cells removed from the graft to reduce the risk of severe graft-versus-host disease. Researchers also give a second infusion of selected donor cells to speed immune recovery. The goal is to see whether this approach is safe and helps these infants survive with a working immune system.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A refined donor-cell transplant using TCRα/β-depleted and CD45RA-depleted cells
What this could lead to
If it works, this approach could give infants with SCID a safer transplant option when no matched sibling donor exists, rebuilding immunity without severe graft-versus-host disease.
What could go wrong
This is a small, early-phase trial in a fragile infant population. The transplant may fail to engraft, infections may still occur, or graft-versus-host disease may develop despite the cell-depletion strategy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

4 people

The number who actually took part.

Started

Sep 2021

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - Transplant Recipient * Age ≥2 months old at the time of chemotherapy administration * A proven mutation as defined by direct sequencing of patient DNA * Has a suitable matched sibling donor or matched unrelated donor (8/8) or single haplotype matched (≥3 of 6) family member donor * Patient must fulfill pre-transplant evaluation: * Left ventricular ejection fraction \>40% and no evidence of uncorrected congenital malformation with clinical symptomatology * Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/min/1.73m2 or serum Creatinine ≤1.2mg/dL * Resting pulse oximetry ≥90% on room or ≥95% on oxygen supplementation * Lansky (age-dependent) performance score ≥50 * Bilirubin ≤3 times the upper limit of normal for age * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age Exclusion Criteria - Transplant Recipient * Positive for HIV infection by genome PCR * Presence of active malignancy * A social situation indicating that the family may not be able to comply with protocol procedures and recommended medical care * Presence of a medical condition indicating that survival will be dismal such as the requirement for mechanical ventilation, severe failure of a major organ system, or evidence of a serious, progressive infection that is refractory to medical therapy Inclusion Criteria - Matched Sibling Donor and Haplocompatible Donor * Fully matched sibling donor (8/8), or matched unrelated donor (8/8), or at least single haplotype matched (≥3 of 6) family member * At least 1 year old (MSD) and at least 18 years of age (Haplocompatible) * HIV negative * Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female) * Not breast feeding * Regarding donation eligibility, is identified as either: * Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR * Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe combined immunodeficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.